Seaport Therapeutics (SPTX) investor relations material

Company overview and business model

• Clinical-stage therapeutics company focused on developing novel oral medicines for depression, anxiety, and neuropsychiatric disorders using a proprietary lymphatic-targeting prodrug platform (Glyph).

• Lead candidates include GlyphAllo (oral allopregnanolone prodrug) for major depressive disorder (MDD) and GlyphAgo (oral agomelatine prodrug) for generalized anxiety disorder (GAD).

• Pipeline includes preclinical programs such as Glyph2BLSD (oral 2-bromo-LSD prodrug) for treatment-resistant depression, PTSD, and headache disorders.

• Retains exclusive, worldwide development and commercialization rights to all product candidates and discovery programs.

• Business strategy centers on leveraging the Glyph platform to address limitations of existing neuropsychiatric drugs and create new intellectual property.

Financial performance and metrics

• Net loss of $74.9 million for the year ended December 31, 2025, compared to $46.9 million in 2024.

• Research and development expenses increased to $66.3 million in 2025 from $25.1 million in 2024, reflecting pipeline advancement.

• General and administrative expenses were $21.0 million in 2025, down from $27.3 million in 2024, primarily due to lower stock-based compensation.

• Cash, cash equivalents, and investments totaled $233.7 million as of December 31, 2025.

• Accumulated deficit of $114.1 million as of December 31, 2025.

Use of proceeds and capital allocation

• Net proceeds from the IPO, together with existing cash, will fund clinical development of GlyphAllo through Phase 2b topline data and into Phase 3, GlyphAgo through Phase 2a and 2b topline data, and Glyph2BLSD through first-in-human studies.

• Additional funds allocated to research and development for other programs, working capital, and general corporate purposes.

• May use a portion of proceeds for in-licensing, acquisitions, or investments in complementary businesses or technologies.